Copyright
©The Author(s) 2015.
World J Transplant. Dec 24, 2015; 5(4): 310-319
Published online Dec 24, 2015. doi: 10.5500/wjt.v5.i4.310
Published online Dec 24, 2015. doi: 10.5500/wjt.v5.i4.310
Table 2 Reasons for conversion to everolimus
| Reason for conversion | Percentage | 95%CI |
| Nephrotoxicity | 30.00% | 24.0-36.0 |
| CAV | 20.50% | 15.2-25.8 |
| Malignancy | 17.20% | 12.1-21.9 |
| Nephrotoxicity + CAV | 9.80% | 5.9-13.7 |
| Nephrotoxicity + neoplasms | 7.00% | 3.6-10.4 |
| CAV + malignancy | 2.00% | 0.2-3.8 |
| Others | 13.00% | 8.6-17.4 |
- Citation: Manito N, Delgado JF, Crespo-Leiro MG, Arizón JM, Segovia J, González-Vílchez F, Mirabet S, Lage E, Pascual-Figal D, Díaz B, Palomo J, Rábago G, Sanz M, Blasco T, Roig E. Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients. World J Transplant 2015; 5(4): 310-319
- URL: https://www.wjgnet.com/2220-3230/full/v5/i4/310.htm
- DOI: https://dx.doi.org/10.5500/wjt.v5.i4.310